Stocks › TGTX
TG THERAPEUTICS, INC.
TGTX·Nasdaq·
United States·USD
United States·USD$52.19
-1.72 (-3.19%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
TGTX
TG THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
TGTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of TGTX by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
TGTXTG THERAPEUTICS, INC. · Stock |
Sale $1,001 - $15,000 |
Nov 6, 2020 | Sep 8, 2020 | Filing ↗ |
Whale Activity
Position changes in TGTX reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 2.6M | $145.4M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by TGTX insiders, by quarter · Form 4
Recent Insider Transactions
192 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Charney Laurence NDirector · Director | Sale | −5,000 | $54.96 | $275K | Sep 10, 2026 | Form 4 ↗ |
| Charney Laurence NDirector | Gift | −13.2K | $0.00 | $0 | Jan 29, 2026 | Form 4 ↗ |
| Charney Laurence NDirector | Gift | −30.0K | $0.00 | $0 | Jan 28, 2026 | Form 4 ↗ |
| WEISS MICHAEL SCEO · Director | Grant / award | +622.0K | $0.00 | $0 | Jan 8, 2026 | Form 4 ↗ |
| Power Sean ACFO | Grant / award | +90.0K | $0.00 | $0 | Jan 8, 2026 | Form 4 ↗ |
| Echelard YannDirector | Sale | −5,000 | $32.57 | $163K | Nov 24, 2025 | Form 4 ↗ |
| WEISS MICHAEL SCEO · Director | Gift | −803.7K | $0.00 | $0 | Nov 5, 2025 | Form 4 ↗ |
| WEISS MICHAEL SCEO · Director | Gift | −3.9M | $0.00 | $0 | Nov 5, 2025 | Form 4 ↗ |
| Lonial SagarDirector | Sale | −20.9K | $32.24 | $672K | Sep 11, 2025 | Form 4 ↗ |
| Echelard YannDirector | Sale | −10.0K | $36.94 | $369K | Jun 13, 2025 | Form 4 ↗ |
| Echelard YannDirector | Grant / award | +14.7K | $0.00 | $0 | Jun 12, 2025 | Form 4 ↗ |
| Charney Laurence NDirector | Grant / award | +21.4K | $0.00 | $0 | Jun 12, 2025 | Form 4 ↗ |
| Hoberman KennethDirector | Grant / award | +14.7K | $0.00 | $0 | Jun 12, 2025 | Form 4 ↗ |
| HUME DANIELDirector | Grant / award | +14.7K | $0.00 | $0 | Jun 12, 2025 | Form 4 ↗ |
| Lonial SagarDirector | Grant / award | +14.7K | $0.00 | $0 | Jun 12, 2025 | Form 4 ↗ |
| HUME DANIELDirector | Gift | −62.5K | $0.00 | $0 | Mar 17, 2025 | Form 4 ↗ |
| Charney Laurence NDirector | Gift | −6,000 | $0.00 | $0 | Mar 10, 2025 | Form 4 ↗ |
| WEISS MICHAEL SCEO · Director | Grant / award | +750.0K | $0.00 | $0 | Jan 29, 2025 | Form 4 ↗ |
| Power Sean ACFO | Grant / award | +87.5K | $0.00 | $0 | Jan 29, 2025 | Form 4 ↗ |
| Power Sean ACFO | Sale | −10.0K | $28.53 | $286K | Jan 6, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding TGTX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 7.9M | $436.2M | 0.39% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.4M | $240.5M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.7M | $205.3M | 0.25% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $173.7M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.1M | $117.3M | 1.09% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $100.0M | 0.21% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $83.0M | 0.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $82.8M | 0.24% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 1.3M | $73.8M | 0.48% | Jun 30, 2026 |
| Congress Small Cap Growth Fund Professionally Managed Portfolios | 1.3M | $67.6M | 3.37% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list TGTX's shares (CUSIP 88322Q108), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming TG THERAPEUTICS, INC. as client
No lobbying filings found naming TG THERAPEUTICS, INC. as the client.
Government Contracts
Federal awards to TG THERAPEUTICS, INC. · USAspending
No federal contract awards found for TG THERAPEUTICS, INC..
U.S. Patents
Recent USPTO applications naming TG THERAPEUTICS, INC.
No USPTO patent applications found for TG THERAPEUTICS, INC..
Annual Financials
From TGTX's 10-K filings · XBRL
No annual XBRL figures on record for TGTX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 3-for-169Reverse splitApr 30, 2012
- 1-for-50Reverse splitJul 14, 2011
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
About TG THERAPEUTICS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE
SEC CIK0001001316 ↗
Former namesMANHATTAN PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, ATLANTIC PHARMACEUTICALS INC